Vera Bril
Co-Applicant
Professor of Neurology at University of Toronto | Neurologist and Director of the Neuromuscular Section at University Health Network and the University of Toronto
Senior Scientist at the Toronto General Research Institute
NMD4C Involvement: Pillar 2: Clinical Research, Pillar 3: Clinical Practice Research
Biography
Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of the Neuromuscular Section, Division of Neurology, University of Toronto and University Health Network. She directs the Ellen & Martin Prossserman Centre for Neuromuscular Diseases at the University Health Network, and the Prosserman Family Neuromuscular Clinic and the Elisabeth Raab Neurofibromatosis Clinic at Toronto General Hospital. She has particular expertise in the diagnosis and management of patients with complex neuromuscular disorders. Her research interests have centered on the diagnosis and evidence-based treatment of myasthenia gravis, inflammatory polyneuropathies, and diabetic sensorimotor polyneuropathy leading to publication of more than 350 journal articles.
Recent Publications
Idiaquez, JF, Barnett-Tapia, C, Perkins, BA, Bril, V. Assessing corneal dendritic cells in glucose dysregulation small-fibre neuropathy. J Peripher Nerv Syst. 2024. PMID:39532698
Hanna, A, Ing, EB, Sundaram, AN, Bril, V, Sharma, RA. Late-Onset Mitochondrial Neurogastrointestinal Encephalopathy Presenting With Isolated Ophthalmic Findings. J Neuroophthalmol. 2024. PMID:39527508
Hadden, RDM, Andersen, H, Bril, V, Basta, I, Rejdak, K, Duff, K et al.. Long-term safety and tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE-CIDP 3 trial. J Peripher Nerv Syst. 2024. PMID:39523874
Bril, V, Berkowicz, T, Szczudlik, A, Nicolle, MW, Bednarik, J, Hon, P et al.. Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial. Muscle Nerve. 2024. PMID:39506903
Habib, AA, Sacconi, S, Antonini, G, Cortés-Vicente, E, Grosskreutz, J, Mahuwala, ZK et al.. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. Ther Adv Neurol Disord. 2024.17 17562864241273036 PMID:39297052
Bhandari, V, Sivadasan, A, Barnett-Tapia, C, Katzberg, H, Bril, V. Using jitter analysis with concentric needle electrodes to assess disease status and treatment responses in myasthenia gravis. Clin Neurophysiol Pract. 2024.9 227-232 PMID:39224193
Bril, V, Lampe, J, Cooper, N, Kiessling, P, Gardulf, A. Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis. J Comp Eff Res. 2024.13 (9)e230171 PMID:39115099
Bhandari, V, Abraham, A, Lovblom, LE, Bril, V. Single simple question in axonal polyneuropathy. Muscle Nerve. 2024.70 (4)824-830 PMID:39114923
Menon, D, Alharbi, M, Katzberg, HD, Bril, V, Mendoza, MG, Barnett-Tapia, C et al.. Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study. Neurology. 2024.103 (4)e209722 PMID:39079067
Francisco Idiaquez, J, Khandelwal, A, Nassar, BA, Thoni, AJ, Mann, A, Prasad, C et al.. Canadian guidance for diagnosis and management of acute hepatic porphyrias. Clin Biochem. 2024.131-132 110792 PMID:38992557
See more on PubMed